A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to study the safety and efficacy (how well it works) of cabozantinib at different dose levels combined with atezolizumab in treating patients with a variety of cancer types.
Urothelial carcinoma (includes cancer of the bladder, urethra, ureter, and renal pelvis), renal cell carcinoma (kidney cancer), castration-resistant prostate cancer (CRPC), non-squamous non-small cell lung cancer(NSCLC), triple negative breast cancer(TNBC), ovarian cancer(OC), endometrial cancer(EC), hepatocellular cancer(HCC), gastric/gastroesophageal junction cancer(GC/GEJC), colorectal cancer(CRC), head and neck (H&N)cancer, or differentiated thyroid cancer(DTC).
Male and Female subjects at least 18 years of age.
Cancer diagnosis of one of the above cancers.
18 - 100
Healthy Volunteers Needed
Duration of Participation
You may receive study treatment as long as your cancer does not get worse, you do not have medically unacceptable side effects, and your study doctor judges your condition to be appropriate for this study.
Knight Clinical Trial Information